anaesthetics: sevofluorane
ApprovedSmall molecule
anaesthetics: sevofluorane is one of 12 small molecule programs targeting Myelopathy. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Myelopathy
#DrugCompanyPhaseTrials
1Immunoglobulin
SanofiApproved
Prialt
TTerezinha de Jesus Esteves Barata
Approved
Rilutek
AAzurity Pharmaceuticals
Phase 3
Rituxan
RochePhase 2
Ibudilast
UUniversity of California, Los Angeles
Phase 3
KW-0761
Kyowa Kirin Co., Ltd.Phase 3
anaesthetics: sevofluorane
UUniversity of Roma La Sapienza
Approved
Methionine
SSt. Jude Children's Research Hospital
Phase 3
Zidovudine/lamivudine
GileadPhase 3
Limaprost
SSeoul National University Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anaesthetics: sevofluorane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Roma La Sapienza